Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
Palvella Therapeutics provided its full year 2025 financial results and updated on its clinical development programs. The company announced positive Phase 3 SELVA study results for QTORIN™ rapamycin for microcystic lymphatic malformations with plans to submit an NDA in the second half of 2026 and potential FDA approval in early 2027. Additional Pha…